We are live on !
Find out more
HighMark Wealth Management Portfolio holdings
AUM
$299M
Turnover
13.67%
1-Year Est. Return
53.01%
This Fund
S&P 500
This Quarter Est. Return
+21.77%
1 Year Est. Return
+53.01%
3 Year Est. Return
+109.68%
5 Year Est. Return
+113.63%
10 Year Est. Return
–
AUM
$299M
AUM Growth
+$52.9M
(+22%)
Cap. Flow
+$8.26M
Cap. Flow % of AUM
Cap. Flow %
2.77%
Top 10 Holdings %
Top 10 Hldgs %
65.82%
Holding
600
New
46
Increased
156
Reduced
94
Closed
36
Avg Time Held
Equity + Options
3.4
years
Top 10 Avg Time Held
Equity + Options
2.7
years
Top 20 Avg Time Held
Equity + Options
2.3
years
Avg Time Held Equity only
3.4
years
Top 10 Avg Time Held Equity only
2.7
years
Top 20 Avg Time Held Equity only
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Health Care Index ETF
FHLC
|
+$18.3M |
| 2 |
SI-BONE Inc
SIBN
|
+$3.79M |
| 3 |
Duos Technologies
DUOT
|
+$2.91M |
| 4 |
Apogee Therapeutics
APGE
|
+$2.91M |
| 5 |
Neuropace
NPCE
|
+$1.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$9.41M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$5.14M |
| 3 |
AnaptysBio
ANAB
|
+$3.29M |
| 4 |
iShares MSCI EAFE Value ETF
EFV
|
+$1.64M |
| 5 |
Piper Sandler
PIPR
|
+$1.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 64.9% |
| 2 | Healthcare | 21.84% |
| 3 | Technology | 4.77% |
| 4 | Financials | 3.58% |
| 5 | Industrials | 1.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
MSGK
451
MSG Knickerbockers Corp.
MSGK
$7.47B
| $2.41K | ﹤0.01% |
6
| – | – |
2023 Q4
10 quarters
|
|
452
Rentokil
RTO
$12.1B
| $2.4K | ﹤0.01% |
84
-9
| -10% | -$286 |
2026 Q1
1 quarter
|
|
453
Blackstone
BX
$95.9B
| $2.4K | ﹤0.01% |
20
| – | – |
2025 Q4
2 quarters
|
|
454
Definium Therapeutics
DFTX
$4.36B
| $2.35K | ﹤0.01% |
50
-50
| -50% | -$1.24K |
2022 Q1
17 quarters
|
|
455
Honeywell
HON
$70.9B
| $2.24K | ﹤0.01% |
+10
| New | +$2.23K |
2026 Q2
0 quarters
|
|
456
Inspire Medical Systems
INSP
$1.94B
| $2.23K | ﹤0.01% |
50
| – | – |
2024 Q2
8 quarters
|
|
|
HONA
457
Honeywell Aerospace
HONA
$50.1B
| $2.21K | ﹤0.01% |
+10
| New | +$2.21K |
2026 Q2
0 quarters
|
|
458
Zymeworks
ZYME
$2.08B
| $2.09K | ﹤0.01% |
80
| – | – |
2020 Q2
24 quarters
|
|
459
iShares Core S&P US Growth ETF
IUSG
$32.1B
| $2.08K | ﹤0.01% |
11
| – | – |
2025 Q2
4 quarters
|
|
460
Destiny Tech100
DXYZ
$788M
| $2.06K | ﹤0.01% |
+80
| New | +$3.01K |
2026 Q2
0 quarters
|
|
461
Palo Alto Networks
PANW
$288B
| $2.05K | ﹤0.01% |
6
| – | – |
2021 Q1
21 quarters
|
|
462
Liquidia Corp
LQDA
$3.75B
| $1.99K | ﹤0.01% |
25
-25
| -50% | -$1.34K |
2024 Q2
8 quarters
|
|
463
Check Point Software Technologies
CHKP
$14.4B
| $1.97K | ﹤0.01% |
15
| – | – |
2025 Q3
3 quarters
|
|
464
MP Materials
MP
$6.83B
| $1.96K | ﹤0.01% |
35
| – | – |
2025 Q3
3 quarters
|
|
465
Northern Oil and Gas
NOG
$2.75B
| $1.95K | ﹤0.01% |
107
+1
| +0.9% | +$24 |
2025 Q2
4 quarters
|
|
466
Digital Turbine
APPS
$1.03B
| $1.94K | ﹤0.01% |
150
| – | – |
2020 Q4
22 quarters
|
|
467
Haleon
HLN
$38.5B
| $1.93K | ﹤0.01% |
207
-139
| -40% | -$1.29K |
2024 Q1
9 quarters
|
|
468
Bicycle Therapeutics
BCYC
$254M
| $1.84K | ﹤0.01% |
435
| – | – |
2021 Q3
19 quarters
|
|
469
The Mosaic Company
MOS
$6.05B
| $1.84K | ﹤0.01% |
87
+1
| +1% | +$23 |
2019 Q4
26 quarters
|
|
470
DuPont de Nemours
DD
$19.1B
| $1.76K | ﹤0.01% |
13
| – | – |
2019 Q4
26 quarters
|
|
471
Annexon
ANNX
$747M
| $1.71K | ﹤0.01% |
300
| – | – |
2021 Q2
20 quarters
|
|
472
SAP
SAP
$270B
| $1.71K | ﹤0.01% |
11
-5
| -31% | -$853 |
2019 Q4
26 quarters
|
|
473
Toll Brothers
TOL
$14.1B
| $1.66K | ﹤0.01% |
10
| – | – |
2025 Q1
5 quarters
|
|
474
Versant Media Group
VSNT
$4.5B
| $1.63K | ﹤0.01% |
45
-23
| -34% | -$924 |
2026 Q1
1 quarter
|
|
475
ARS Pharmaceuticals
SPRY
$303M
| $1.6K | ﹤0.01% |
+200
| New | +$1.72K |
2026 Q2
0 quarters
|
|
Similar funds
BOC
HighMark Wealth Management's Q2 2026 Portfolio in Review
As of Q2 2026, HighMark Wealth Management held 600 positions worth $299M, up 22% from $246M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
HighMark Wealth Management's Q2 2026 filing shows 46 new, 156 increased, 94 reduced and 36 closed positions. Its largest new stake was Duos Technologies: 289,884 shares worth $3.48M. The largest sale was Centessa Pharmaceuticals, an estimated $9.41M.
By sector, the portfolio is most concentrated in Miscellaneous at 65% of assets, down from 65% a quarter earlier, followed by Healthcare and Technology.
- HighMark Wealth Management's largest Q2 2026 buy was Duos Technologies: 289,884 shares worth $3.48M.
- HighMark Wealth Management added most to Fidelity MSCI Health Care Index ETF in Q2 2026, an estimated $18.3M increase.
- HighMark Wealth Management's biggest Q2 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $5.14M.
- HighMark Wealth Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $9.41M.
- HighMark Wealth Management's ten largest holdings make up 66% of its $299M portfolio in Q2 2026.
- HighMark Wealth Management opened 46 new positions and closed 36 in Q2 2026.
- HighMark Wealth Management's portfolio value rose 22% quarter-over-quarter to $299M.
Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.